Maravai LifeSciences Holdings, Inc. MRVI R2KR3KPHARMA
Company Overview
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Recent Developments
- Dec 2025 Revenue of $185.74M (-28.3% YoY); net profit $-130.77M.
- Trailing 12 Months Year-on-year growth — revenue +40.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.44% |
| 1 Year: | 40.50% |
Stock Price Performance
| 1 Year: | +166.18% |
| 6 Months: | +106.20% |
| 3 Months: | +45.82% |
| 1 Month: | +17.12% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MRVI Maravai LifeSciences Holdings, Inc. R2KR3KPHARMA | 7.32 | -10.31 | $1.08B | 0.00% | -29.66% | -40.98% | 4.44% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.98M | 46.91M | 87.86M | 148.21M | 217.78M | 204.81M | 244.29M | 242.73M | 191.26M | 79.03M | 68.91M | 66.86M | 64.18M | 69.42M | 69.03M | 46.85M | 47.40M | 41.63M | 65.84M | 51.44M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.23M | 7.72M | - | 5.66M | 33.70M | 20.65M |
| Operating Income | 34.82M | 8.12M | 45.72M | 91.19M | 153.53M | 155.38M | 167.37M | 180.70M | 116.90M | 2.53M | -11.61M | -15.42M | -18.86M | -13.44M | -165.61M | -49.16M | -66.28M | -41.03M | -2.16M | -15.09M |
| Net Income | 23.39M | 1.42M | 38.95M | 23.10M | 49.14M | 53.96M | 66.86M | 71.24M | 44.47M | -67.00K | -6.54M | -6.46M | -12.08M | -9.79M | -97.07M | -29.95M | -39.59M | -25.56M | -3.73M | -12.42M |
| Diluted EPS | 0.09 | 0.00 | 0.12 | 0.24 | 0.44 | 0.44 | 0.50 | 0.53 | 0.34 | 0.00 | -0.05 | -0.05 | -0.09 | -0.07 | -0.68 | -0.21 | -0.27 | -0.18 | -0.02 | -0.08 |
| R&D Expense | 3.74M | 1.60M | 1.87M | 2.16M | 1.93M | 1.95M | 3.69M | 4.27M | 5.39M | 4.14M | 4.19M | 4.35M | 5.03M | 4.92M | 4.70M | 4.89M | 4.88M | 3.84M | 3.89M | 3.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 143.14M | 284.10M | 799.24M | 883.00M | 288.94M | 259.19M | 185.74M |
| Gross Profit | - | - | - | - | 140.20M | 108.31M | 33.99M |
| Operating Income | 23.99M | 119.90M | 554.64M | 574.22M | -31.65M | -235.62M | -215.27M |
| Net Income | -4.47M | 88.97M | 182.04M | 220.21M | -119.03M | -144.85M | -130.77M |
| Diluted EPS | -0.03 | 2.36 | 1.56 | 1.67 | -0.90 | -1.05 | -0.90 |
| R&D Expense | 3.63M | 9.30M | 15.22M | 18.37M | 17.28M | 19.22M | 17.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Oct 2020 | Dec 2020 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.27B | 1.92B | - | 2.28B | 1.49B | 1.44B | 1.28B | 1.01B | 770.58M |
| Total Equity | 144.63M | - | 88.51M | 315.50M | - | 545.22M | 416.75M | 434.73M | 344.90M | 325.29M | 212.38M |
| Cash & Equivalents | - | - | - | - | - | 632.14M | 574.96M | 573.17M | 578.16M | 322.40M | 216.89M |
| Long Term Debt | - | 400.00M | 528.61M | 524.59M | 544.00M | 522.00M | 518.71M | 517.08M | 516.28M | 290.49M | 286.33M |
| Total Liabilities | - | - | 1.12B | 1.37B | - | 1.38B | 697.57M | 671.26M | 665.56M | 431.04M | 397.87M |
| Current Liabilities | - | - | 130.78M | 93.78M | - | 110.14M | 87.47M | 68.62M | 63.71M | 56.97M | 44.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 24.11M | 152.19M | 368.57M | 535.98M | 126.22M | 7.46M | -57.57M |
| Investing Cash Flow | -17.15M | 6.07M | 105.66M | -267.61M | -122.31M | -24.32M | -31.41M |
| Financing Cash Flow | -4.17M | 53.21M | -159.05M | -187.50M | -61.09M | -235.71M | -16.50M |
| Capital Expenditure | -17.15M | -25.41M | -14.85M | -17.09M | -65.55M | -29.66M | -13.15M |
| Free Cash Flow | 6.97M | 126.78M | 353.72M | 518.89M | 60.67M | -22.19M | -70.72M |
| Share Buybacks | 0 | 33.66M | 0 | 0 | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 48.5% | 41.8% | 18.3% |
| Operating Margin % | 16.8% | 42.2% | 69.4% | 65.0% | -11.0% | -90.9% | -115.9% |
| Net Margin % | -3.1% | 31.3% | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% |
| ROE % | -3.1% | 100.5% | 57.7% | 40.4% | -28.6% | -44.5% | -61.6% |
| ROCE % | - | 10.5% | 30.4% | 26.4% | -2.3% | -24.8% | -29.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | GTCR, LLC | 13.52% | 20.15M | $154.75M |
| 2 | Blackrock Inc. | 6.69% | 9.97M | $76.58M |
| 3 | Braidwell LP | 5.84% | 8.70M | $66.84M |
| 4 | 12 West Capital Management Lp | 4.74% | 7.06M | $54.22M |
| 5 | Millennium Management Llc | 4.37% | 6.51M | $49.98M |
| 6 | Vanguard Capital Management LLC | 3.55% | 5.28M | $40.58M |
| 7 | Ophir Asset Management Pty Ltd | 3.24% | 4.83M | $37.07M |
| 8 | Renaissance Technologies, LLC | 3.09% | 4.61M | $35.38M |
| 9 | Deutsche Bank AG | 2.89% | 4.30M | $33.06M |
| 10 | First Eagle Investment Management, LLC | 2.46% | 3.67M | $28.20M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MRVI
Maravai (MRVI) Q2 2026 Earnings Call Transcript
Revenue grew 8.5% to $51.4 million as mRNA discovery demand surged.
Maravai LifeSciences Q2 Earnings Call Highlights
Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast. Revenue for the quar…
How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance
Price target work on Maravai LifeSciences Holdings has shifted, with updated modeling lifting the estimated fair value per share from US$4.33 to US$5.70. Analysts are tying this move to refreshed assumptions that reflect recent Q4 results a…
Maravai (MRVI) Q1 2026 Earnings Transcript
As you can see from the agenda on Slide 2, our CEO, Bernd Brust, will provide a business update and our CFO, Rajesh Asarpota, will review our financial results. At Cygnus, revenue grew a little more than 1% year over year.…
Maravai LifeSciences Q1 Earnings Call Highlights
Maravai LifeSciences (NASDAQ:MRVI) reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from Cygnus, and the impact of restructuring ac…
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates
Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +121.41% and +20.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?…
MRVI — Frequently Asked Questions
What is the current share price of Maravai LifeSciences Holdings, Inc. (MRVI)?
As of 2026-09-07 16:24 PDT, Maravai LifeSciences Holdings, Inc. (MRVI) trades at $7.32 on NasdaqGS. Its 52-week range is $2.33 to $9.00.
What is the market capitalisation of MRVI?
Maravai LifeSciences Holdings, Inc. (MRVI) has a market capitalisation of $1.08B on NasdaqGS.
What is the P/E ratio of MRVI?
MRVI trades at a trailing price-to-earnings (P/E) ratio of -10.31. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.34.
What is the return on equity (ROE) of MRVI?
MRVI has a return on equity (ROE) of -40.98%. Its return on capital employed (ROCE) is -29.66%.
Is MRVI a good stock to buy?
This page provides a data-driven analysis of Maravai LifeSciences Holdings, Inc. (MRVI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.